Highland Therapeutics Inc., of Toronto, said its wholly owned subsidiary, Ironshore Pharmaceuticals and Development Inc., inked an agreement with Quotient Clinical, of Nottingham, U.K., to conduct scintigraphy imaging of its inflammatory bowel disease (IBD) candidate, HLD-400, using Quotient’s Rapidfact (rapid formulation development and clinical testing) program. Ironshore will provide Quotient with technical support and access to Ironshore’s drug delivery platform, Delexis, in return for Quotient’s GMP manufacturing facility and clinical expertise in scintigraphy.